Table Of Content

Subject index of volume 107 Abuse liability assessment 315 Chronic 405 Electroencephalogram 195 Acetylcholine 415, 437, 541 Chronic schizophrenia 175 Electrophysiology 1 ACTH 50 Cigarette 442 Elevated X-maze 405 Activation 50 Cigarette smoking 211 Endogenous 69 Activity 385 Circling 303 Ethanol 11, 78, 125, 132, 337, 385, Acute 405 CL 218,872 347 447, 453, 511, 564 Acute tolerance 511 Classical conditioning 365 Ethology 551 Q@>2-adrenoceptors 132, 497 Clonidine-induced behaviours 497 Ethopharmacology 457 Aetiology 97 [H]Clonidine 132 Evoked brain potentials 50 Age 485 Cocaine 55, 73, 186, 217, 221, 271, Exploratory behaviour 415 Aggression 297, 551 523 Extrapyramidal syndromes 18 Aging 78, 144, 437 Cocaine recognition site 186 Agonistic behavior 551 Coffee drinking 211 Feeding rate 359 AJ 76 73 Cognition 394, 437 Fenfluramine 327 Akathisia 23 Cognition enhancers 144 Fentanyl 319 Alcohol 125, 180, 551 Cognitive dysfunction 485 Field potentials 195 Alcohol withdrawal 97 Cognitive performance 83 Fixed-ratio schedule 315 Alpha-methyl-p-tyrosine 39 Concurrent reinforcers 211 Flesinoxan 474 Alpha-2 receptor 575 Conditioned place aversion 453 Flight 457 Alprazolam 535 Conditioned place preference 221, 385, Flumazenil 103, 180, 310, 347 Alzheimer’s disease 437 453, 564 Flunitrazepam 11 1-Aminocyclopropanecarboxylic acid Conditioned withdrawal 517 Fluoxetine 1, 359 489 Conditioning 277, 523 Fluprazine 113 Amnesia 347 Contingent sensitization 290 Food intake 113, 447 Amphetamine 140, 271, 290, 297, 331, Core body temperature 341 Forced swim test 489 337 Corticosterone 229, 331 Frequency analysis 195 d-Amphetamine 55, 425 Cortisol 50 Frontal cortex 415 Analgesia 595 Craving 523 FR-10 511 Animal behavior 551 Cue learning 347 Anorexia 140, 359 GABA 541 Antidepressant 1 GBR12909 186 Defense 457 Antidepressants 474, 497, 569 Generalized anxiety disorder 535 Dementia 144 Antipsychotic drugs 503 Gepirone 135 Deoxyglucose 30 Anxiety 135, 347, 379 Glycine 489 Dependence 480 Apomorphine 341, 431 Goe 5438 447 Depression 503, 569 Arousal 442 Guinea-pig 581 Diazepam 11, 61, 347, 405 Arousal modulation theory 442 Differential-reinforcement-of-low-rate Attention 394, 425, 541 Haloperidol 18, 290, 331, 453 (DRL) 72-s 474 Hamster 517 Discrimination 541 Barbiturates 125 HAS/LAS 564 Discriminative stimulus 117 Basal forebrain 541 Heart rate 523, 535 Discriminative-stimulus effects 217 Behavior 1, 55, 78, 103, 217 High 352 L-dopa 203 Behavioral economics 211 Hippocampus 415 Dopamine 160, 203, 277, 285, 303, Behavioral experience 290 5-HT 379 394, 415, 431 Behavioural development 221 5-HT, antagonists 61 Dopamine autoreceptor 73 Benzodiazepine 347 5-HT>2 receptors 135 Dopamine receptor subtypes 18 Benzodiazepine antagonists 103 5-HT3 receptors 140 Dopamine receptors 23 Benzodiazepine receptors 180, 310 5-HT,, agonist 474 Dopamine release 303 Benzodiazepines 69, 103, 125, 379 5-HT,, receptors 135 Dopamine system 453 Betablockers 61 5-HT,, receptor and 5-HT. receptor DR mice 125 Bicuculline 541 327 Drinking behavior 447 Bipolar disorder 503 5-HT,¢c receptors 379 Drug discrimination 73, 103, 303 Blood pressure 535 Human 255 Drug interactions 217 BMY 21502 485 Human brain 132, 180 Drug plasma concentration 11 Bromocriptine 277 Human breast milk 69 Drug self-administration 211, 315 [?H]Bromoxidine (UK 14304) 132 Human subjects 535 Drug sensitivity 11 Bupropion 303 Humans 211, 319, 352 DS mice 125 Burying behaviour 61 6-Hydroxydopamine 203, 285 D1 agonist 217 5-Hydroxytryptamine 373 D2 agonist 217 Caffeine 55 8-Hydroxy-2(di-N-propylamino)tetralin D-2 antagonists 236 Calcitonin 50 30 D,, Dz DA receptors 39 cAMP 1 Hypoactivity 497 D2 agonist 415 Cardiac vagal control 535 D2 receptors 277 Catalepsy 117 Idazoxan 405 Ca?* channel inhibitors 447 Imipramine 535 CGRP 50 EEG 569 Inbred mice 385 Chlordiazepoxide 310 EEG activity 236 inbred mice (DBA/2J) 453 m-Chlorophenylpiperazine 229 Electroconvulsive shock 497 Indatraline 186 Subject index of volume 107 Abuse liability assessment 315 Chronic 405 Electroencephalogram 195 Acetylcholine 415, 437, 541 Chronic schizophrenia 175 Electrophysiology 1 ACTH 50 Cigarette 442 Elevated X-maze 405 Activation 50 Cigarette smoking 211 Endogenous 69 Activity 385 Circling 303 Ethanol 11, 78, 125, 132, 337, 385, Acute 405 CL 218,872 347 447, 453, 511, 564 Acute tolerance 511 Classical conditioning 365 Ethology 551 Q@>2-adrenoceptors 132, 497 Clonidine-induced behaviours 497 Ethopharmacology 457 Aetiology 97 [H]Clonidine 132 Evoked brain potentials 50 Age 485 Cocaine 55, 73, 186, 217, 221, 271, Exploratory behaviour 415 Aggression 297, 551 523 Extrapyramidal syndromes 18 Aging 78, 144, 437 Cocaine recognition site 186 Agonistic behavior 551 Coffee drinking 211 Feeding rate 359 AJ 76 73 Cognition 394, 437 Fenfluramine 327 Akathisia 23 Cognition enhancers 144 Fentanyl 319 Alcohol 125, 180, 551 Cognitive dysfunction 485 Field potentials 195 Alcohol withdrawal 97 Cognitive performance 83 Fixed-ratio schedule 315 Alpha-methyl-p-tyrosine 39 Concurrent reinforcers 211 Flesinoxan 474 Alpha-2 receptor 575 Conditioned place aversion 453 Flight 457 Alprazolam 535 Conditioned place preference 221, 385, Flumazenil 103, 180, 310, 347 Alzheimer’s disease 437 453, 564 Flunitrazepam 11 1-Aminocyclopropanecarboxylic acid Conditioned withdrawal 517 Fluoxetine 1, 359 489 Conditioning 277, 523 Fluprazine 113 Amnesia 347 Contingent sensitization 290 Food intake 113, 447 Amphetamine 140, 271, 290, 297, 331, Core body temperature 341 Forced swim test 489 337 Corticosterone 229, 331 Frequency analysis 195 d-Amphetamine 55, 425 Cortisol 50 Frontal cortex 415 Analgesia 595 Craving 523 FR-10 511 Animal behavior 551 Cue learning 347 Anorexia 140, 359 GABA 541 Antidepressant 1 GBR12909 186 Defense 457 Antidepressants 474, 497, 569 Generalized anxiety disorder 535 Dementia 144 Antipsychotic drugs 503 Gepirone 135 Deoxyglucose 30 Anxiety 135, 347, 379 Glycine 489 Dependence 480 Apomorphine 341, 431 Goe 5438 447 Depression 503, 569 Arousal 442 Guinea-pig 581 Diazepam 11, 61, 347, 405 Arousal modulation theory 442 Differential-reinforcement-of-low-rate Attention 394, 425, 541 Haloperidol 18, 290, 331, 453 (DRL) 72-s 474 Hamster 517 Discrimination 541 Barbiturates 125 HAS/LAS 564 Discriminative stimulus 117 Basal forebrain 541 Heart rate 523, 535 Discriminative-stimulus effects 217 Behavior 1, 55, 78, 103, 217 High 352 L-dopa 203 Behavioral economics 211 Hippocampus 415 Dopamine 160, 203, 277, 285, 303, Behavioral experience 290 5-HT 379 394, 415, 431 Behavioural development 221 5-HT, antagonists 61 Dopamine autoreceptor 73 Benzodiazepine 347 5-HT>2 receptors 135 Dopamine receptor subtypes 18 Benzodiazepine antagonists 103 5-HT3 receptors 140 Dopamine receptors 23 Benzodiazepine receptors 180, 310 5-HT,, agonist 474 Dopamine release 303 Benzodiazepines 69, 103, 125, 379 5-HT,, receptors 135 Dopamine system 453 Betablockers 61 5-HT,, receptor and 5-HT. receptor DR mice 125 Bicuculline 541 327 Drinking behavior 447 Bipolar disorder 503 5-HT,¢c receptors 379 Drug discrimination 73, 103, 303 Blood pressure 535 Human 255 Drug interactions 217 BMY 21502 485 Human brain 132, 180 Drug plasma concentration 11 Bromocriptine 277 Human breast milk 69 Drug self-administration 211, 315 [?H]Bromoxidine (UK 14304) 132 Human subjects 535 Drug sensitivity 11 Bupropion 303 Humans 211, 319, 352 DS mice 125 Burying behaviour 61 6-Hydroxydopamine 203, 285 D1 agonist 217 5-Hydroxytryptamine 373 D2 agonist 217 Caffeine 55 8-Hydroxy-2(di-N-propylamino)tetralin D-2 antagonists 236 Calcitonin 50 30 D,, Dz DA receptors 39 cAMP 1 Hypoactivity 497 D2 agonist 415 Cardiac vagal control 535 D2 receptors 277 Catalepsy 117 Idazoxan 405 Ca?* channel inhibitors 447 Imipramine 535 CGRP 50 EEG 569 Inbred mice 385 Chlordiazepoxide 310 EEG activity 236 inbred mice (DBA/2J) 453 m-Chlorophenylpiperazine 229 Electroconvulsive shock 497 Indatraline 186 Indorenate 61 Normals 480 Reward 385, 453 Insomnia patients 480 Novelty hypoalgesia 575 Ritanserin 405 Interaction 511 Nucleus accumbens 285 Roman strains 415 Interdose interval 290 Route of administration 217, 255 Interindividual differences 11 Object recognition 415 RU 41656 415 Interval analysis 551 Ondansetron 140, 405 Intoxication 97 Ontogeny 39 Saccharin consumption 447 Ipsapirone 61, 405 Ontogeny of locomotor activity 221 SCH 23390 341, 591 IRT>tschedule 373 Operant 511 Schizophrenia 425, 503 Operant behavior 186 SCH 23390 18, 23 Ketamine 431 Operant behaviour 373 Scopolamine 243, 263, 437 Ketanserin 135, 359, 379 Opiate 117 Sedation 236, 347, 497 Opiate withdrawal 595 Seizures 97 Latent inhibition 425 Opiates 297, 319 Selective breeding 125 Lateralisation of function 425 Self-administration 255, 271 Learning 55, 243, 365, 394, 485, 530 Para-chloroamphetamine 327 Self-mutilation 39 Lesch-Nyhan syndrome 39 Parkinson's disease 203, 394 Sensitization 271, 277, 290, 331 Lesion 373 Pavlovian conditioning 203 Sensorimotor function 160 Liking 352 Pentobarbital 352 Sensory processing 50 Locomotion 277, 297, 551 Pentylenetetrazol 457 Sequential analysis 551 Locomotor 337 D-Pen?, p-Pen® enkephalin 581 Serotonin 1, 30, 229, 327, 415, 474 Locomotor activity 229, 453, 564, 581 Pharmacogenetics 385 Sexual behavior 89, 327 Locomotor behavior 595 Pharmacokinetics 352 Sibutramine hydrochloride 303, 497 Locomotor stimulation 125 Phenylpiperazine 113 SKF 38393 39, 217, 341, 431 Loperamide 89 Physostigmine 541 Skin resistance 523 Lu 19-005 186 Place conditioning 385 Skin temperature 523 LY 171555-induced hyperactivity 591 Place learning 3473 Sleep 83, 569 LY53857 327 Placebo controlled trial 175 Smoking 442 Plus-maze test 135 Smoking motive 442 Mammillary gland 69 Positron emission tomography 23, 180 Social interaction 379 Man 425 Postsynaptic a@-adrenoceptors 497 Sodium cromoglycate 595 Marijuana 117, 255 Precipitated withdrawal 517 Sodium pentobarbital 365 Mecamylamine 530 Preference 447 Spatial alternation behavior 263 Memory 83, 394, 437, 530 Presynaptic a@2-adrenoceptors 497 Spontaneous alternation 415 Mesolimbic dopamine 285 Prolactin 229 Spontaneous locomotion 347 Metachlorophenylpiperazine 30 Psychogenetic selection 415 Squirrel monkeys 55, 217, 315 Metergoline 359 Psychomotor performance 11, 319 Staircase test 310 Methamphetamine 303 Psychomotor stimulant theory 385 Stereoisomers 315 3-Methoxytyramine 303 Stereoselectivity 186 Methylnaloxone 89 Quinpirole 39, 217, 341, 581 Stereotypy 431 Mianserin 379 Quipazine 30 Stress 331, 442 Milk intake 290 Striatum 415 MK-801 243, 431, 489 Rabbit 236, 365 Subjective effects 255, 319 MK-801 induced hypermotility 591 Raclopride 23 Submission 457 Monoamine uptake inhibitor 186 Radial maze 415 Sulpiride 341 Mood 319 Radioreceptor assay 69, 186 Morphine 55, 89, 385, 517, 581 Rat 97, 195, 236, 347, 373, 405, 457, Tardive dyskinesia 503 Morphine pellets 517 474, 575, 591 Taurine 337 Morris water maze 347, 485 Rate of increase 352 Telemetry 195 Motivation 160 Rats 113, 117, 243, 511, 564 Temperature dependence 186 Motor activity 297, 551 Reaction time 78 Temporal differentiation 373 Motor control 160 Rearing 337 A°-Tetrahydrocannabinol 55, 117 Mouse 221, 310 Rebound insomnia 480 THC 255 Muscimol 541 Receptors 1 Thigmotaxis 347 Mydriasis 497 Receptors, 5-HT,,, 5-HT,,, 5-HT2 229 Tolerance 78, 511 Rehearsal 263 Trazodone 569 Naloxone 310, 517, 575 Reinforcement 285 Triazolam 83, 480 Neuroendocrine 1 Reinforcer interactions 211 Triazolopyridazine 347 Neuroleptic 117 Reinforcing effects 255 Neuroleptics 18, 175, 195, 236 Reinforcing effects of drugs 315 (+)-UH 232 73 Neurotransmitters 229 Relapse prevention 175 U50,488H 581 Nicotine 271, 285, 442 Relapse rates 175 Nicotinic cholinergic receptors 530 Remoxipride 175, 236 Water intake 113 Nictitating membrane response 365 Repeated acquisition 55, 243 Withdrawal 297, 405, 523 Nitrous oxide 310 Repeated transitions 243 Working memory 263, 415 N-methyl-b-aspartate 489 Repeated treatment 591 N,N-dimethylamphetamine 315 Reserpine 39 YM 09151-2 591 Nonhuman primates 18 Reserpine and mice 341 Nootropics 144 Respiratory sinus arrhythmia 535 Noradrenaline 415, 575 Response chains 55 Zolpidem 83